Danaher (DHR) Stock Price, News & Analysis

+17.03 (+7.21%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
6.88 million shs
Average Volume
2.78 million shs
Market Capitalization
$187.44 billion
P/E Ratio
Dividend Yield
Price Target

Danaher MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
6.0% Upside
$268.27 Price Target
Short Interest
0.94% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.68mentions of Danaher in the last 14 days
Based on 35 Articles This Week
Insider Trading
Selling Shares
$8.27 M Sold Last Quarter
Proj. Earnings Growth
From $7.62 to $8.72 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Multi-Sector Conglomerates Sector

1st out of 16 stocks

Process Control Instruments Industry

1st out of 12 stocks

DHR stock logo

About Danaher Stock (NYSE:DHR)

Danaher Corporation, founded in 1984 by brothers Stephen and Mitchell Rales, is a globally diversified conglomerate headquartered in Washington, D.C. The company has evolved into a major player across various industries, offering a wide range of products and services in the medical, industrial, and commercial sectors. Danaher's mission is to innovate and provide high-quality solutions that positively impact people's lives worldwide. Danaher's began in 1984 as a Massachusetts real estate investment trust called DMG, Inc. The company underwent several reorganizations and strategic acquisitions, culminating in its present-day structure and diverse product portfolio.

Danaher is involved in designing, manufacturing, and marketing a broad array of products and services. Its offerings span medical diagnostics equipment, life sciences and diagnostics tools, environmental solutions, water quality analysis systems, industrial automation tools, and other specialized instruments. Danaher's mission is to leverage its technological expertise and commitment to continuous improvement to develop innovative solutions that enhance human well-being and drive sustainable growth.

The company's diverse product portfolio includes cutting-edge medical diagnostic devices, scientific instruments used in research and healthcare settings, water quality monitoring systems, and automation equipment for industrial applications. Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation. Its products and services find applications in research institutions, healthcare facilities, industrial manufacturers, and government organizations.

Danaher Corporation boasts a leadership team comprising highly accomplished individuals with diverse expertise, driving the company's success and strategic direction. At the helm is Steven M. Rales, the Co-Founder and Chairman, who played a pivotal role in establishing Danaher and has been instrumental in shaping its strategic vision. With his visionary approach, Rales has steered the company towards sustained growth and innovation. Rainer M. Blair holds the positions of President, Chief Executive Officer, and Director, leading Danaher's day-to-day operations and spearheading its growth strategies. Blair's dynamic leadership has been crucial in driving the company's expansion and ensuring its position as a market leader.

Danaher has displayed excellent financial performance in recent years, with consistent revenue growth and profitability. The company's financial stability and strategic acquisitions have contributed to its robust performance. Danaher's strong financials indicate its ability to generate revenue and profits, which has positively influenced investor sentiment and contributed to its favorable valuation.

Danaher's valuation metrics demonstrate positive investor sentiment and confidence in the company's future growth prospects. Its favorable price-to-earnings ratio and price-to-cash flow ratio reflect investor willingness to pay a premium for its earnings potential and cash generation capacity. Danaher's stock performance has been noteworthy, driven by its strong financials, strategic initiatives, and positive market sentiment.

Investors should closely monitor any recent news or events that may have impacted Danaher's share price, such as industry developments or major acquisitions. Danaher operates in diverse industries with various competitors. Its competitive advantages, including a broad product portfolio and emphasis on innovation, position it well within its industries.

Danaher has ample growth opportunities, including expansion into emerging markets, strategic acquisitions, and research and development investments. The company's strong focus on continuous improvement and customer-centric solutions will drive its pursuit of growth opportunities.

Danaher faces potential risks and challenges, including market fluctuations, regulatory changes, and economic uncertainties. However, its proactive risk management strategies mitigate potential impacts on the company's financial performance.

DHR Stock Price History

DHR Stock News Headlines

Heartland Express: Q1 Earnings Snapshot
Putin and other countries have a plan
Did you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon.
Stocks to Watch Tuesday: GM, Spotify, UPS, Tesla
Danaher Shrugs Off Outlook for Falling Sales
Putin and other countries have a plan
Did you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon.
Danaher Issues Q2, FY24 Guidance - Quick Facts
Danaher Reports First Quarter 2024 Results
Danaher (NYSE:DHR) Shares Gap Down to $239.39
Danaher (NYSE:DHR) Upgraded by HSBC to Buy
HSBC Upgrades Danaher (DHR)
Contrasting Danaher (NYSE:DHR) & OncoCyte (NASDAQ:OCX)
Danaher (DHR) to Release Quarterly Earnings on Tuesday
DHR Quantitative Stock Analysis
Veralto: A Solid Start Since The Spin-Off
See More Headlines
Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/26 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 4/26 Dividend
Next Earnings (Confirmed)
Dividend Payable
Fiscal Year End

Industry, Sector and Symbol

Process control instruments
Industrial Conglomerates
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$4.76 billion
Pretax Margin


Sales & Book Value

Annual Sales
$23.89 billion
Cash Flow
$11.40 per share
Book Value
$72.39 per share


Free Float
Market Cap
$187.65 billion

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Should I Buy Danaher Stock? DHR Pros and Cons Explained


Here are some ways that investors could benefit from investing in Danaher Co.:

  • Danaher Co. has a strong financial position with a low debt-to-equity ratio of 0.31, indicating a healthy balance between debt and equity.
  • The company has consistently increased its dividend payout, with a recent boost from $0.24 to $0.27 per share, showcasing a commitment to rewarding shareholders.
  • Recent insider transactions, such as the sale of shares by SVP Georgeann Couchara and Director Teri List, may indicate confidence in the company's future performance.
  • Danaher Co. reported earnings per share of $2.09 for the last quarter, surpassing analyst estimates by $0.18, demonstrating strong financial performance.
  • With a market capitalization of $188.47 billion, Danaher Co. is a well-established conglomerate with a significant presence in the market, offering stability to investors.


Investors should be bearish about investing in Danaher Co. for these reasons:

  • The stock price of Danaher Co. has experienced volatility, with a 12-month low of $182.09 and a high of $259.00, which may pose risks for short-term investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

DHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Danaher stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DHR shares.
View DHR analyst ratings
or view top-rated stocks.

What is Danaher's stock price target for 2024?

15 brokerages have issued twelve-month target prices for Danaher's shares. Their DHR share price targets range from $205.00 to $300.00. On average, they expect the company's share price to reach $268.27 in the next year. This suggests a possible upside of 6.0% from the stock's current price.
View analysts price targets for DHR
or view top-rated stocks among Wall Street analysts.

How have DHR shares performed in 2024?

Danaher's stock was trading at $231.34 on January 1st, 2024. Since then, DHR shares have increased by 9.4% and is now trading at $253.11.
View the best growth stocks for 2024 here

Are investors shorting Danaher?

Danaher saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,350,000 shares, an increase of 12.2% from the March 15th total of 5,660,000 shares. Based on an average daily volume of 2,710,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.9% of the company's shares are short sold.
View Danaher's Short Interest

When is Danaher's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our DHR earnings forecast

How were Danaher's earnings last quarter?

Danaher Co. (NYSE:DHR) issued its quarterly earnings data on Tuesday, January, 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. The conglomerate had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a trailing twelve-month return on equity of 12.25%. Danaher's revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.87 EPS.
Read the conference call transcript

How often does Danaher pay dividends? What is the dividend yield for Danaher?

Danaher announced a quarterly dividend on Wednesday, February 21st. Investors of record on Thursday, March 28th will be given a dividend of $0.27 per share on Friday, April 26th. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date is Wednesday, March 27th. This is a positive change from the stock's previous quarterly dividend of $0.24.
Read our dividend analysis for DHR

Is Danaher a good dividend stock?

Danaher (NYSE:DHR) pays an annual dividend of $1.08 per share and currently has a dividend yield of 0.46%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 16.90%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 12.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?

27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).

Who are Danaher's major shareholders?

Danaher's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.28%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.23%), Raymond James & Associates (0.18%), Vaughan Nelson Investment Management L.P. (0.12%), Fifth Third Bancorp (0.07%) and Douglas Lane & Associates LLC (0.04%). Insiders that own company stock include Alan G Spoon, Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel Raskas, Elias A Zerhouni, Georgeann Couchara, Jennifer Honeycutt, Joakim Weidemanis, Jose-Carlos Gutierrez-Ramos, Linda Filler, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Raymond C Stevens, Robert S Lutz, Teri List and Walter G Lohr.
View institutional ownership trends

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Danaher have any subsidiaries?
The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
This page (NYSE:DHR) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners